MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.breast.2022.05.008

Медицинская библиотека · Breast (Edinburgh, Scotland) · 2022

Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials.

Pfaffendorf Charlotte, Vonthein Reinhard, Krockenberger-Ziegler Katja, Dellas Kathrin, Schreiber Andreas, Uhlemann Dorit, Dinges Stefan, Würschmidt Florian, Andreas Peter, Weinstrauch Evelyn, Eilf Kirsten, Rades Dirk, Höller Ulrike, Combs Stephanie E, Kazmierczak Renata, Fehlauer Fabian, Schreck Ulrike, Zimmer Jörg, Dunst Jürgen, Krug David

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

PURPOSE: To analyze long-term results of two multicenter prospective single-arm trials (ARO-2010-01 and ARO-2013-04) investigating adjuvant hypofractionated radiotherapy (HF) with simultaneous integrated boost (SIB) after breast-conserving surgery (BCS).

METHODS

Eligible patients had histopathologically confirmed unifocal breast cancer planned for whole breast irradiation plus boost radiotherapy to the tumor bed. In both studies, a total dose of 40 Gy was applied to the whole breast and of 48 Gy to the tumor bed in 16 fractions of 2.5 and 3.0 Gy. Radiotherapy could be given either as three-dimensional conformal radiotherapy (3D-CRT) or as intensity-modulated radiotherapy (IMRT). The primary study objectives were feasibility and security within an observation period of six months. The current investigation focuses on long-term efficacy and toxicities.

RESULTS

Between 2011 and 2014, both trials enrolled 300 patients in total. Data from 274 of these patients could be used for the current analysis. The median follow-up time was 60 months and the 5-year disease-free survival 92.1%. Three patients suffered a local recurrence (after 36-72 months) while a regional recurrence occurred in one patient (after 17 months). The 5-year local control rate in the breast was 99.6%. 63.5% of all patients did not report any late radiation-related toxicity, 28.5% reported grade 1 and 7.3% grade 2 toxicities. The highest late toxicity was grade 3 in 2 women (0.7%, telangiectasia and lymphedema of the breast).

CONCLUSION

Our analysis demonstrates favorable efficacy and low rates of long-term side effects of HF with SIB after BCS. Randomized controlled phase III trials are ongoing.

Для цитирования: Pfaffendorf Charlotte, Vonthein Reinhard, Krockenberger-Ziegler Katja, Dellas Kathrin, Schreiber Andreas, Uhlemann Dorit, Dinges Stefan, Würschmidt Florian, Andreas Peter, Weinstrauch Evelyn, Eilf Kirsten, Rades Dirk, Höller Ulrike, Combs Stephanie E, Kazmierczak Renata, Fehlauer Fabian, Schreck Ulrike, Zimmer Jörg, Dunst Jürgen, Krug David. Hypofractionation with simultaneous integrated boost after breast-conserving surgery: Long term results of two phase-II trials.. Breast (Edinburgh, Scotland). 2022. DOI: 10.1016/j.breast.2022.05.008.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.